

# Eastwood Bio-Medical Canada Inc. (EBM)

July 4, 2018

2018年7月4日



1130-4871 Shell Road, Richmond, BC, Canada V6X3Z6



## Forward-Looking Statement / 前瞻性陳述

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Eastwood Bio-Medical Canada Inc. (the Company) and the Company's affiliates, including expectations and assumptions concerning TSX Venture Exchange approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.



**Eastwood Bio-Medical Canada Inc. is located at Richmond, British Columbia, Canada near the Vancouver International Airport.**

**Eastwood Bio-Medical Canada Inc. 位於加拿大卑詩省列治文， 臨近溫哥華國際機場。**

# Canadian History in Diabetes Leadership

## 加拿大是糖尿病行業的全球先驅

Canada has long been considered the global pioneer of diabetes industry. In 1922, Frederick Grant Banting discovered insulin, which is considered one of the most important discoveries of the 20th century. The Nobel Foundation awarded his team Nobel Prize in Physiology and Medicine in 1923.

人們長期以來一直將加拿大視為糖尿病行業的全球先驅。1922年，弗雷德里克·班廷(Frederick Grant Banting)發現了胰島素，這被認為是20世紀最重要的發現之一。諾貝爾基金會於1923年授予弗雷德里克·班廷的團隊諾貝爾生理學和醫學獎。



# Who We Are

## 關於我們

**A biomedical research and development company specializing in metabolic disorders such as diabetes, obesity, hypertension, and Alzheimer's disease.**

一家生物醫學研發公司，致力於研究糖尿病、肥胖症、高血壓和阿爾茨海默病等代謝紊亂疾病的解決方案。

**We have successfully developed over 70 Eleotin® products including over 50 Health Canada (Canadian FDA) approved products.**

我們已經成功開發了**70**多種**Eleotin®**產品，其中包括**50**多種加拿大衛生部（加拿大**FDA**）批准的產品。

**Advertising Standards Canada (ASC) approved our flagship product, Eleotin® Bentley to be marketed as “World's #1 Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.**


加拿大廣告標準委員會**(ASC)**批准本公司的旗艦產品**Eleotin® Bentley**用“**世界第一**醫生推薦的純天然加拿大健康血糖促進產品”名義進行市場推廣。



医生推荐世界第一：3000+  
 电视报纸报道范围最广：2500  
 第三方临床实验世界最多：7  
 各国糖尿病协会极力推荐：4  
 获得各国卫生部批号世界最多：9  
 有记录的产品使用者世界最多：500,000+  
 实现血糖正常化的天然草本产品

## 世界第一医生推荐的加拿大纯天然血糖健康促进产品

这是加拿大广告标准局 (ASC) 于2014年12月15日批准使用的广告语，广告批号：DP536486-E



100%纯天然  
 100%科学验证  
 100%安全无副作用  
 实现血糖正常化  
 修复新陈代谢引发的综合症  
 获加拿大及中国等先进国家卫生部许可，无需医生处方

ASC  
Approval  
Number

ASC批准  
文號



东林公司微信公众号



东林公司微信号

Eastwood Bio-Medical Research Inc.  
 Unit 1130-4871 Shell Road  
 Richmond, B.C. Canada, V6X 3Z6  
 Tel No.: 604.247.2100  
 Toll Free No.: 1.888.669.4372  
 Email: info@eastwoodcos.com

# Who We Are

## 關於我們

**Over 500,000 users are estimated to have used and benefited from Eleotin®.**

估計有超過**500,000**名使用者用過**Eleotin®**並從中受益。

**More than four international diabetes associations strongly recommend (endorsed) Eleotin®.**

超過四個國際糖尿病協會強烈推薦（認可）**Eleotin®**。

**Eleotin® was the recipient of 2010 Best Metabolism Disorder Treatment of the Year Award and**

**Eleotin®獲得2010年度最佳新陳代謝紊亂治療獎和**

**7th Annual International Brand Packing Awards**

**第七屆年度國際品牌包裝獎**

## EBM: The Recent Focus of Financial Analysts and Investors EBM：金融分析師和投資者近期所關注的焦點

Company production capacity ‘recently’ has increased to:

公司產能“最近”實現增長：

- Up to 3 million capsules can be produced and 10,000 bottles can be packaged per day.  
每天可生產多達300萬粒膠囊，每天可包裝10,000瓶膠囊。
- A half million dollar worth of products in retail value can be produced daily.  
每天可生產零售價值達\$50萬的產品。
- Up to \$7 million in possible savings in annual manufacturing costs.  
所節約的年度製造成本高達\$700萬。





# EBM: The Recent Focus of Financial Analysts and Investors

EBM：金融分析師和投資者近期所關注的焦點



# EBM: The Recent Focus of Financial Analysts and Investors

EBM：金融分析師和投資者近期所關注的焦點

**New Product Approvals and Licenses (45 NPN Numbers).**  
新產品批號和許可證（45 NPN批號）。



## June 29 2018, Eastwood Bio-Medical Canada Enters Binding Terms for Asian Exports

2018年6月29日, Eastwood Bio-medical Canada Inc. 簽訂產品出口亞洲協議

- On June 29 2018, EBMC announced to enter binding terms for Asian exports. Accordingly, 900% increase in revenue was announced.

2018年6月29日, EBMC宣佈與一家亞洲分銷公司就採購訂單達成具有約束力的條款。因此, EBMC宣佈收入增加900%。

- New manufacturing capabilities allow us to finally start producing highly advanced and complex products with the best quality and process control on a meaningfully larger scale.


新的製造能力令我們能夠大幅提高產能, 採用最佳的工藝控制技術, 開始生產非常先進、複雜的高品質產品。

- EBMC is no longer being bound by production limitations. EBMC不再受產量限制的約束。

# Stock Prices in the Past 6 Months


## 過去6個月股價

The market has begun paying attention.  
市場開始關注本公司。




# Trading Volume in the Past 6 Months

## 過去六個月成交量



# Market Potential: Prevalence of Diabetes By IDF Region

市場潛力：國際糖尿病聯盟地區的糖尿病患病率




## Market Potential: Prevalence of Alzheimer's and Dementia

市場潛力：阿爾茨海默氏症和癡呆症的患病率

全球的阿爾茨海默氏症和癡呆症患者

Alzheimer's and dementia patients worldwide




# Market Potential: Prevalence of Hypertension

市場潛力：高血壓病的患病率

Global Prevalence of Hypertension  
over 1.3 Billion

全球有超過13億高血壓病患者





## Market Values of Diabetes, Hypertension and Alzheimer's 糖尿病、高血壓和阿爾茨海默氏症的市場規模

- **Type 2 diabetes market to more than double, to \$64 billion by 2026**  
治療2型糖尿病的市場規模將增加一倍以上，到**2026**年達到**\$640**億
- **Global hypertension market will reach USD \$32 billion by the end of 2020**  
到**2020**年底，全球治療高血壓病的市場規模將達到**320**億美元。
- **The global Alzheimer's market is expected to \$10.4 billion in 2021**  
預計到**2021**年，全球治療阿爾茨海默氏症的市場規模將達**\$104**億

## **Our Claim: The Only Option**

我們的主張：我們的產品是患者的唯一選擇

**We believe that our products are the ‘only’ option for those inflicted with these diseases.**

我們相信，我們的產品是患有這些疾病的患者的“唯一”選擇。

**We also believe we will remain the only option in the near future.**

我們也相信，在不久的將來，我們的產品仍將是患者的唯一選擇。

**Here is why...**

理由是...

# Advantage #1: Modes of Action Known

Pharmaceutical Drugs and Insulin	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/ Alternative Treatments	Eleotin®
Known - Can be used with other pharmaceutical drugs	Unknown	Unknown	Unknown	Known - Can be safely used with other pharmaceutical drugs

- The Modes of Actions for most non-pharmaceutical treatments are unproven. They can not be used with pharmaceutical drugs out of fear of unknown adverse interactions.
- Eleotin®'s modes of actions are known and proven. Eleotin® is safe when used with oral pharmaceutical drugs and insulin.
- In fact, Eleotin® reduces the side effects and resistance of oral pharmaceutical drugs and insulin. When used with Eleotin®, oral pharmaceutical drugs and insulin become safer more efficacious and less habit forming.

## 優勢1：作用機制已知

藥物和胰島素	其他草藥	中藥	民間療法 /非傳統 療法	Eleotin®
已知——可與 其他藥物一起 使用	未知	未知	未知	已知——可安 全地與其他藥 物一起使用

- 大多數非藥物療法的作用機制尚未得到證實。由於擔心未知的不良相互作用，非藥物療法不能與藥物一起使用。
- **Eleotin®**的作用機制眾所周知。當**Eleotin®**與口服藥物和胰島素一起使用時，**Eleotin®**安全有效。
- 事實上，**Eleotin®**能減少口服藥物和胰島素的副作用和抗藥性。當口服藥物和胰島素與**Eleotin®**一起使用時，能實現安全有效的療效並減少藥物依賴。

# Advantage #2: Long Term Effects

## 優勢 2：長期影響

Pharmaceutical Drugs and Insulin 藥物和胰島素	Other Herbal Products 其他草藥	Traditional Chinese Medicine 中藥	Folkloric Treatments/ Alternative Treatments 民間療法/非傳統療法	Eleotin®
None 無	None 無	Unknown 未知	None 無	Semi-permanent efficacy 半永久性的長期改善

- **With proven insulin resistance reduction, Eleotin® provides semi-permanent long term improvement while other treatments do not give such long term benefits.**  
隨著胰島素抗病力的降低，Eleotin®可提供半永久性的長期疾病改善，而其他治療方法則無法帶來長期效益。
- **Most other treatments only have short term control benefits, and must be used permanently.**  
大多數其他療法只有在短期內控制疾病，必須永久使用這些療法。
- **But a person can stop Eleotin® with no harmful side effects after the body has attained structural change.** 但使用Eleotin®的患者在身體實現結構變化後，可以停止使用Eleotin®並且沒有任何有害副作用。

## Advantage #3: Preventive Effects

### 優勢3：預防效果

Pharmaceutical Drugs and Insulin 藥物和胰島素	Other Herbal Products 其他草藥	Traditional Chinese Medicine 中藥	Folkloric Treatments/ Alternative Treatments 民間療法/非傳統療法	Eleotin®
No 否	No 否	No 否	No 否	Yes 是

- A person who does not have diabetes can use Eleotin® for general health and preventive purposes. Other treatments do not offer such safe options.  
非糖尿病患者可以用Eleotin®改善健康狀況和進行糖尿病預防。其他療法無法提供這一安全選項。

# Conclusion 結論

<b>Pharmaceutical Drugs and Insulin</b> 藥物和胰島素	<b>Other Herbal Products</b> 其他草藥	<b>Traditional Chinese Medicine</b> 中藥	<b>Folkloric Treatments/ Alternative Treatments</b> 民間療法/非傳統療法	<b>Eleotin®</b>
<p>Short term and invasive treatment. Toxic and severe side effects. Resistance develops. Ever increasing dosages.</p> <p>短期和侵入性治療、有毒和嚴重的副作用、產生抗藥性、需要不斷提高劑量。</p>	<p>Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar</p> <p>突擊式營銷。大多依靠人為製造消化不良來降低血糖</p>	<p>Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar</p> <p>突擊式營銷。大多依靠人為製造消化不良來降低血糖</p>	<p>Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar</p> <p>突擊式營銷。大多依靠人為製造消化不良來降低血糖</p>	<p><b>Long term and safe beneficial effects. General health improvements.</b></p> <p>長期安全的療效，改善總體健康狀況</p>

- **If you compare Eleotin® with other treatments from all perspectives, it's natural to conclude that Eleotin® is the only option.**

如果您從所有角度比較Eleotin®與其他療法，就能自然地得出結論：**Eleotin®**是唯一的選擇。

# As a Result, 因此,

ASC approved Eleotin® to be “**World’s #1** Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.

加拿大廣告標準委員會(ASC)批准Eleotin用“加拿大市場上**全球首個**醫生推薦的天然來源健康血糖促進產品”名義進行市場推廣。

- **World’s No.1 Doctor recommended: Over 3000+ doctors** / 全球首個醫生推薦：逾**3000**名醫生推薦
- **Over 2,500 Newspaper & Television Acclaims (including New York Times #1 Best Sellers)** / 得到超過**2500**條報紙和電視臺讚譽（包括《紐約時報》排名第一的暢銷書）
- **Researched/Clinically tested by Universities and Governments** / 由大學和政府進行研究/臨床測試
- **Strongly recommended by more than 4 International Diabetes Associations** / 得到**4**個以上國際糖尿病協會的強烈推薦
- **Licenses issued by 8 Government Authorities** / 獲得**8**個政府機關簽發的許可證
- **Best Metabolism Disorder Treatment of the Year 2010 Award Winner** / 獲得**2010**年度最佳新陳代謝紊亂治療獎
- **More than 500,000 Users as of beginning of this year** / 截至今年年初，已有超過**500,000**名使用者
- **Over 2,000 Youtube testimonials** / 超過**2,000**個Youtube視頻推薦



# International Diabetes Associations Endorsements of Eleotin®

## 國際糖尿病協會認可Eleotin®

### 糖尿病教育报

主办：南京三友医药保健品公司  
南京三友医药保健品有限公司  
南京三友医药保健品有限公司  
南京三友医药保健品有限公司

(特刊)  
教育资料  
注意保存

#### 你已经自由了

“艾莉奥汀”帮助糖尿病患者摆脱困境  
——南京三友医药保健品公司总经管理家一言家

艾莉奥汀(上海三友医药保健品有限公司)是一种非胰岛素促泌剂，能刺激胰岛β细胞分泌胰岛素，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复...



艾莉奥汀(上海三友医药保健品有限公司)是一种非胰岛素促泌剂，能刺激胰岛β细胞分泌胰岛素，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复...

艾莉奥汀(上海三友医药保健品有限公司)是一种非胰岛素促泌剂，能刺激胰岛β细胞分泌胰岛素，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复，使胰岛β细胞分泌胰岛素的能力得到恢复...

### 医药信息

#### 새 “당뇨병치료물질” 개발

**“천연약초서 추출……부작용 전혀 없어”  
EBMR서 공동발표**  
캐나다 갈가리대 외대 당뇨연구센터와 개발 과프너인 EBMR사는 천연약초에서 새로운 당뇨병 치료물질인 ‘P-700’을 개발했다고 공동 발표했다. 이에 앞서 EBMR사는 이미 ‘P-700’을 이용한 건강차 ‘엘레오틴’을 지난 1월부터 북미지역에서 판매하기 시작했으며, 당뇨병 치료용 개발을 추진중이다.

공동개발자인 EBMR사는 캐나다 밴쿠버 소재의 의료기업인 이스트우드사(생명과학 사업)의 자회사로 당뇨병과 암 치료제를 전문적으로 개발중인 신약개발 전문회사다. ‘P-700’으로 명명된 이 당뇨병 치료물질은 천연약초에서 추출돼 기존 당뇨병 치료제에 비해 부작용이나 내성이 전혀 없는 것으로 나타났다고 갈가리대 학과 EBMR사는 밝혔다.

EBMR사는 “임상실험 결과 ‘P-700’은 혈당을 조절하는 기존 당뇨병치료제에 기능외에도 인슐린을 생산하는 췌장의 베타세포 기능을 강화하고, 근육 조직에서 인슐린을 잡아내는 수송체를 생성하는 효능까지 있다”고 밝혔다.

EBMR사는 “성인병의 대명사로 한랭병으로 알려진 당뇨병을 치료할 수 있는 길을 보여준 셈”이라고 설명했다. 하지만 이런 신약이 개발돼 당뇨병자에게 보급되기까지 걸리는 기간은 대략 7-10년이 걸린다고 한다.

당뇨치료제 개발 캐나다 윤지원박사  
캐나다 연구하는 교프너의 새 ‘P-700’ 당뇨병 치료제 ‘엘레오틴’이 개발된 것이다. ‘엘레오틴’은 천연약초에서 추출된 새로운 당뇨병 치료물질로, 기존의 ‘P-700’을 이용한 건강차 ‘엘레오틴’을 지난 1월부터 북미지역에서 판매하기 시작했으며, 당뇨병 치료용 개발을 추진중이다.

공동개발자인 EBMR사는 캐나다 밴쿠버 소재의 의료기업인 이스트우드사(생명과학 사업)의 자회사로 당뇨병과 암 치료제를 전문적으로 개발중인 신약개발 전문회사다. ‘P-700’으로 명명된 이 당뇨병 치료물질은 천연약초에서 추출돼 기존 당뇨병 치료제에 비해 부작용이나 내성이 전혀 없는 것으로 나타났다고 갈가리대 학과 EBMR사는 밝혔다.

EBMR사는 “임상실험 결과 ‘P-700’은 혈당을 조절하는 기존 당뇨병치료제에 기능외에도 인슐린을 생산하는 췌장의 베타세포 기능을 강화하고, 근육 조직에서 인슐린을 잡아내는 수송체를 생성하는 효능까지 있다”고 밝혔다.

EBMR사는 “성인병의 대명사로 한랭병으로 알려진 당뇨병을 치료할 수 있는 길을 보여준 셈”이라고 설명했다. 하지만 이런 신약이 개발돼 당뇨병자에게 보급되기까지 걸리는 기간은 대략 7-10년이 걸린다고 한다.

약사공론 1998. 10. 8 제 3081호

#### 艾莉奥汀的主要成份是什么?

艾莉奥汀的主要成份是...  
艾莉奥汀的主要成份是...  
艾莉奥汀的主要成份是...

#### 艾莉奥汀对那些人有影响?

艾莉奥汀对那些人有影响...  
艾莉奥汀对那些人有影响...  
艾莉奥汀对那些人有影响...

#### 艾莉奥汀如何服用?

艾莉奥汀如何服用...  
艾莉奥汀如何服用...  
艾莉奥汀如何服用...

#### 艾莉奥汀有没有副作用?

艾莉奥汀有没有副作用...  
艾莉奥汀有没有副作用...  
艾莉奥汀有没有副作用...

#### 艾莉奥汀的安全性和?

艾莉奥汀的安全性和...  
艾莉奥汀的安全性和...  
艾莉奥汀的安全性和...

#### 艾莉奥汀的副作用

艾莉奥汀的副作用...  
艾莉奥汀的副作用...  
艾莉奥汀的副作用...

#### 艾莉奥汀的安全性

艾莉奥汀的安全性...  
艾莉奥汀的安全性...  
艾莉奥汀的安全性...

# Recommendations of Medical Professionals



**Dr. Chu, Beijing China**  
“Because of Eleotin my husband doesn’t need any pharmaceutical drugs. He’s normal now.”



**Dr. J. Yoon**  
“This remedy will restore near normalcy for 70% of Type II diabetics.”



**Dr. L. Lipskaya, Bacteriologist**  
“After I started using Eleotin, I felt an improvement in my health conditions. Now I recommend Eleotin to every person who are suffering from Type II diabetes.”



**Dr. M. Sichel**  
“A pathfinding discovery in the reversal of diabetes.”



**Dr. P. Singh  
Ayurvedic Medicine**  
“I want to recommend Eleotin especially to Type II diabetics. It will help them in controlling their blood glucose levels.”



**Dr. C. L. Broadhurst**  
“Eleotin is blend of many promising herbs that dramatically lower blood sugar.”



**Dr. M. Kuypers**  
“I am using it myself, with great benefit. My own experience have been most encouraging. I am looking forward to finally being able to do something about insulin resistance.”



**Dr. E. Echano**  
“Everyone should know about this. i observed excellent clinical result. This unique herbal formulations long lasting effects are truly amazing.”



**Dr. D. Walker**  
“Eleotin is effective in regulating blood glucose levels.”

# Recommendations of Medical Professionals

## 醫療專業人員推薦



**Chu**博士，中國北京  
“因為**Eleotin**，我的丈夫不需要任何藥物。他現在過著正常健康的生活。”



**J. Yoon**博士 “對於70%的2型糖尿病患者，這種藥物將使患者恢復到接近健康正常的狀態。”



**L. Lipskaya**博士，細菌學家  
“在我開始使用**Eleotin**之後，我感覺自己的健康狀況有所改善。現在我向所有患有II型糖尿病的人推薦**Eleotin**。”



**M. Sichel**博士  
“**Eleotin**是逆轉糖尿病的突破性發現。”



**P. Singh**博士  
阿育吠陀醫學  
“我想特別向II型糖尿病患者推薦**Eleotin**。它將幫助患者控制血糖水平。”



**C. L. Broadhurst**博士  
“**Eleotin**由許多草藥混合而成，可以顯著降低血糖。”



**M. Kuypers**博士  
“我自己使用它，它給我帶來了很大的好處。我自己的經歷是最令人鼓舞的。我期待著能夠對胰島素抗藥性做些什麼。”



**E. Echano** 博士  
“每個人都應該知道這一點。我觀察到**Eleotin**有極好的臨床效果。這種獨特的草藥配方有持久療效，確實令人驚歎。”



**D. Walker**博士  
“**Eleotin**可有效調節血糖水平。”

# Clinical Studies, Publications, Approvals and Licenses

## 臨床研究、出版物、批文和許可證



Technical and Toxicology Report of the Center for Disease Prevention and Control, People's Republic of China

**Testing Report**

Manufacturer/Supplier:	Eleotin
Name of Sample:	Eleotin, International Enterprise Co., Ltd. Sample from Free Trade Zone
Manufacturer:	Eleotin International Enterprise Co., Ltd.
Sample Volume:	200 mg
Expiration Date:	18 months from manufacturing date
Sample Description:	Type: capsule Color: white, round, light brown powder
Amount of Sample Received:	6.1 g (approx. 30 capsules) in 1 bottle
Sample Received on:	May 12, 2004
Testing Criteria:	Sample 1: Eleotin as a supplement in domestic market; Sample 2: Eleotin as a supplement in foreign market
Testing Scheme:	Eleotin Health Products Testing and Evaluation Guidelines (2002)

**Testing Results**  
The results showed that Eleotin had no effect on the blood glucose levels of the normal subjects (reference group) after fasting (0-8h). Compared with the glucose standard control group, Eleotin effectively lowered the blood glucose levels (p < 0.05) in 2511 of normal subjects with previously high blood glucose levels induced by Nilsson in all Eleotin dose groups (High dose, middle dose and low dose). After oral dosing of glucose to all Eleotin dose groups, the blood glucose levels of these groups were not lower than that of the glucose standard control group (0-8h). According to the standards set by National Health Products Testing and Evaluation Guidelines (2002), the testing of whether Eleotin is effective in suppressing the increase of blood glucose level in a normal population showed positive results. Level of proof:



卫生部认定保健食品检测机构  
卫生部卫监发(1996年)第53号

University of Calgary (UTI) officials



Press conference at the launching of the first Eleotin

# Clinical Studies, Publications, Approvals and Licenses

## 臨床研究、出版物、批文和許可證

精品匯 指南

### 成功就是这样简单

——300例糖尿病患者服用博特力效果分析

博特力胶囊在北美上市已有八年，数以万计的糖尿病患者摆脱了困苦。自去年在国内上市以来，已被越来越多的国内糖尿病患者所认可，尤其在调节血糖、预防和改善糖尿病并发症方面，博特力胶囊更显示出它独特的功效。

为了让更多的糖尿病患者了解服用博特力的效果，我们随机抽调了300例正在服用该产品的患者，并做了比较详细的回访分析。

在抽取的300例顾客中，各年龄段的人群都有，年龄最小的23岁，最大的87岁；他们服用博特力的时间长短各异，最短的服用一个月，最长的服用八个月；其中明确诊断为II型糖尿病的256人，糖尿病异常的44人。

在确诊为II型糖尿病的256个顾客中，患病时间、血糖控制情况及并发症、合并症各有不同。有的患者是刚刚被确诊为糖尿病，有的则已确诊多年或数十年；有的患者空腹血糖高，有的只是餐后两小时血糖高，还有二者都高者；从服药情况看，有单纯口服药，有单纯注射胰岛素，也有联合应用者。发病五年以上的患者基本都合并一至多种并发症、合并症，且临床表现症状各异，如手脚麻木疼痛，乏力，失眠，皮肤瘙痒，视力下降等等。

上述顾客在服用博特力胶囊后，70%以上的血糖逐渐平稳，98%并发症有了明显的改

善，有部分顾客已减少降血糖药物的用量，现做如下表格以帮助分析：

#### 一、服用博特力时间，减、停用降血糖药物人数和百分比

服用时间	人数(个)	减、停药人数	百分比
6个月以上	96	62	64.6%
4~6月	142	59	41.5%
2~3月	40	5	12.5%
1个月	22		

#### 二、服博特力前后的血糖及症状比较表

服前的血糖及症状	人数(个)	服后血糖或症状改善人数(个)	有效率
血糖偏高	224	187	83.5%
血糖控制良好	32	32	100%
糖耐量异常	44	39	86.6%
手脚麻木	56	47	83.9%
乏力、易疲劳	65	48	73.8%
皮肤瘙痒	30	22	73%
睡眠欠佳	34	25	73.5%
视力下降	38	16	42.1%
出汗多	26	15	57.7%
口干	43	26	65.1%
夜尿频	49	27	55.1%
足部红肿	3	2	66.7%
阳痿	7	6	85.7%

以上是300例服用博特力顾客的情况分析，通过上述数据我们欣喜地看到博特力胶囊的特殊作用，如果给博特力胶囊充足的时间去滋养和调理身体，就会显示出它独特而强大的效果。既使停用降血糖药物和博特力胶囊，仍能让70%以上的糖尿病患者的血糖维持在正常水平或近乎正常的水平，不会出现反弹。

博特力胶囊之所以有如此强大的效果，是因为博特力胶囊能激发和恢复胰腺的基本功能，促进β细胞的再生和修复，增加胰岛素的分泌；同时还具有恢复胰岛素与受体靶细胞之间结合力作用，减少胰岛素抵抗，提高胰岛素受体和胰岛素的结合率，大大提高了对人体释放胰岛素的利用率，从而充分进行葡萄糖代谢，使机体获得自身调节血糖的能力。

# Clinical Studies, Publications, Approvals and Licenses

## 臨床研究、出版物、批文和許可證

약업신문 1998년 10월 8일 목요일 Executive

캐나다에 거주하는 교포의학자가 참여하고 교포가 운영하는 회사들이 공동으로 획기적인 당뇨병 치료제를 개발한 것으로 알려져 주목되고 있다.

최근 캐나다의 한 교포회사인 EBMR(Eastwood Bio-Medical Research Inc.)사가 발표한 바에 따르면 이번에 개발된 약물

은 700여 차례의 임상실험을 실시한 결과 발병 6개월 이내의 성인형 당뇨병을 70% 이상 치료한 것으로 밝혀졌다.

P-700이라는 이 약물은 전 각종 천연약초에서 추출된 생약물질로 되어 있어 부작용과 내성이 전혀 없다고 EBMR 측은 발표했다.

EBMR은 이 약물이 혈당조절뿐 아니라 인슐린을 생산하는 췌장 베타세포의 기능을 강화하고 근육조직에서 인슐린을 잡아치는 수용체를 다시 살아나게 해 당뇨병을 근본적으로 치료해 준다고 설명했다.

이번 당뇨병 치료제는 캐나다 칼거리대학교 당뇨병연구소가 기초연구 및 동물실험등을 실시했고 제공하는 EBMR측에서 추진하고 있는 것으로 전

ty Technologies International이라는 회사를 통해 EBMR과 상품개발 계약이 체결됐다.

이번 신약개발에 일조한 윤박사는 23년간 바이러스와 관련된 당뇨병의 원인과 예방에 대한 연구로 매우 높은 평가를 받고 있는 것으로 전해졌다.

EBMR측은 "윤박사가 노벨 의학상에 두 번이나 후보 추천된 인물이므로 당뇨병 분야의 세계적인 위자"라고 소개했다.

한편 EBMR사는 로열, 텔레 커뮤니케이션 장비제조, 금융투자, 국제무역등의 관련업무를 하고 있는 이스트우드(Eastwood)의 계열사이며, 의학 관련 벤처기업으로 캐나다에 거주하는 한국인 교포 김영수(42)씨가 운영하는 회사이다.


(민경두기자)

**교포 획기적 당뇨병 치료제 개발**  
**윤지원박사, 700여차례 임상 80% 완치**

### Comments on Eleotin by Korean National Diabetes Association 韓國國家糖尿病協會對 Eleotin的評論

# Clinical Studies, Publications, Approvals and Licenses

## 臨床研究、出版物、批文和許可證



### 새 "당뇨병치료물질" 개발

"천연약초서 추출...부작용 전혀 없어"

EBMR한들 공동발표

캐나다 칼가리대 외대 당뇨연구센터와 개발 파트너인 EBMR사는 천연약초에서 새로운 당뇨병 치료물질 개발하는 데 성공했다고 공동 발표했다.

이에 앞서 EBMR사는 이미 'P-700'을 이용한 건강차 '엘레오틴'을 지난 1월부터 북미지역에서 판매하기 시작했으며, 당뇨병치료 의약품 개발을 추진중이다.

공동개발자인 EBMR사는 캐나다 밴쿠버 소재의 프로그어업인 이스트우드서걸영수 식감의 제일사로 당뇨병과 암치료제를 전문적으로 개발중인 신약개발 전문회사다.

'P-700'으로 명명된 이 당뇨병 치료물질은 천연약초에서 추출돼 기존 당뇨병 치료제에 비해 부작용이나 내성이 전혀 없는 것으로 나타났다고 칼가리대학과 EBMR사는 밝혔다.

EBMR사는 "민상실험 결과 'P-700'은 혈당을 조절하는 기존 당뇨병치료제 기능외에도 인슐린을 생산하는 췌장의 베타세포 기능을 강화하고, 근육 조직에서 인슐린을 잡아내는 수용체를 재생하는 효능까지 있다"고 밝혔다.

EBMR사는 "성인병의 대명사로 난치병으로 알려진 당뇨병을 치료할 수 있는 길을 보여준 셈"이라고 설명했다. 하지만 이런 신약이 개발돼 당뇨병자에게 보급되기까지 걸리는 기간은 대략 7~10년이 걸린다고 한다.

약사공론 1998. 10. 8. 제 3081호

### 당뇨치료제 개발 캐나다 음지원박사

캐나다에 거주하는 고교과학자이던 당뇨 치료제 개발에 열의를 가진 음지원 박사가 최근 캐나다에서 당뇨병 치료제 개발에 성공했다고 밝혔다.

캐나다 캘거리 대학의 음지원 박사는 최근 캘거리대학과 당뇨병연구센터에서 박사학위를 취득한 음지원 박사가 지난 7월 20일 제 1차 임상실험을 통해 개발한 제 3세대 약제의 실험을 당뇨병에 대해서는 10 중 9 이상을 정상으로 돌려 놓을 수 있을 정도로 획기적인 효과를 거두고 있는 것으로 나타났다.

이런 당뇨병 관련 신약은 영주 박사와 EBMR사와 관계있는 한 당뇨병연구센터가 신약연구를 위한 공동연구를 추진한 결과로 신약의 상용화에 대한 권리는 EBMR사가 갖게는 제정됨으로써 음지원 박사는 이같은 신약치료제 개발에 있어 음지원 박사와

관계가 정립되고 있는 것으로 확인되었다. 음지원박사는 지난 17년간 바이엘사와 공동개발 당뇨병과 관련된 약제에 대한 연구를 하여 세계 일류약품사인 인제코 공인 XBS성분표준식약제부품상급 수상한 바 있다.

## Comments on Eleotin by Korean Pharmaceutical Manufacturers' Association

### 韓國藥品製造商協會對 Eleotin的評論

# Africa's Best Diabetic & Hypertension Management Drug in 2010

## 2010年非洲最佳糖尿病和高血壓管理藥物



**INSTITUTE FOR GOVERNMENT RESEARCH & LEADERSHIP TECHNOLOGY**  
Office of the Country Director/CEO (Africa & Middle East)

The Managing Director/CEO  
 Eleotin GP Ltd  
 Goodnews Plaza, Suite A6  
 4B, Agbaku Street, Opebi, Ikeja  
 Lagos State, South West Nigeria

Monday October 4 2010

Dear Sir,

**BEST DIABETIC & HYPERTENSION  
 MANAGEMENT DRUG OF THE YEAR 2010**

In the spirit of Nigeria's 50<sup>th</sup> Independence celebration, Institute for Government Research & Leadership Technology have the honour to make this award in favour of ELEOTIN GP LTD having out performed other companies in the production of fine Diabetic pharmaceuticals in Nigeria.

- 2) Some of the parameters and performance indices used are:
- Your compliance with government regulatory laws and guidelines;
  - your prowess and contribution in the production of drugs;
  - product's high quality and value creation;
  - Corporate Marketing strategy;
  - Product's price and pricing strategy;
  - Product's acceptability, satisfaction and endorsement;
  - corporate general performance and track record;
  - product's unique selling points and competitive edge;
  - customer's continued patronage and or referrals;

2nd floor, Oakland Centre, Australian Embassy Building, Plot 2966, Agosin Street -  
 Federal Capital Territory Maitama District, Abuja, Nigeria.  
 TEL: + 234 - 09 - 4602947, 01 - 7306554, CELL: + 234 - 08030848907, 08057027580 FAX: 09 - 4613117  
 Web site: <http://www.instituteforgovernmentresearch.com>, e-mail: [instituteforgovernmentresearch@igrl.com](mailto:instituteforgovernmentresearch@igrl.com)

**COUNCIL**  
 Prof. Kper Ejorl CFR Professor of Political Science/Public Administration, Chairman Prof. Ben Weabaso CON, SAN Past Minister of Education  
 Chief (Mrs) Precilla Kuye FOM Past President Nigerian Bar Association Prof. Mahmood Marekoti Professor of Government  
 Prof. Tony Ifeanyi Professor of Government Prof. David Geden Professor of Public Leadership  
 Dr. Ikeangbo Chimezie Associate Professor of Political Science & Administrative Studies  
 Moses Ekele Country Director/CEO (Africa & Middle East)





# Testimonials

## 推薦材料



**We have over 5,000 video testimonials on Youtube by users and doctors with all real names and many contact information to verify.**

我們在Youtube上有超過5,000個使用者和醫生的推薦視頻，使用者和醫生提供真實姓名和許多聯繫信息，以驗證真實性。

# Established Retail Lines

## 成熟的產品線



### Eleotin® Bentley

- Helps promote healthy glucose levels.  
有助於促進達到健康血糖水平。
- Long-term blood glucose normalization effects.  
達到長期實現正常血糖的效果。
- General health improvement.  
提升總體健康狀況。



### Eleotin® Ma5

- Powerful anti-oxidation powers that are preserved superbly.  
強大的抗氧化能力，保存完好。
- High quality Vitamin C group ingredients.  
含高品質的維生素C組成份。

# Established Retail Lines

## 成熟的產品線



### Eleotin® LBM

- for hyperactivity of the liver (high blood pressure).  
用於肝過度活躍（高血壓）。
- To cut the vicious cycle between high blood sugar and high blood pressure caused by prescription drugs.  
減少處方藥引起的高血糖和高血壓之間的惡性循環。



### Eleotin® Pedo-Protection Socks

#### Eleotin® 保護襪

- Anti-Fungal & Anti-Bacterial  
抗真菌和抗菌
- Auto Regulating Mesh Top  
自動調節頂部網狀設計
- Treated Inner Toe Seam  
腳趾縫舒適
- Holistic & Gentle Neck Pressure  
舒緩腳脖壓力

# Founder - Dr. Youngsoo Kim

## 創始人 - 金榮洙博士



- Advises Various Governments and senior management of numerous Korean firms including Hyundai, Gold Star, and Samsung  
為各個政府、包括現代、金星和三星在內的眾多韓國企業的高級管理人員提供建議
- CEO of Mutsumi Enterprises Canada Corp.  
Mutsumi Enterprises Canada Corp. 首席執行官
- Vice President of Toshin Butsuryu (Toyota Automobile Group Japan)  
東新物流株式會社（豐田（日本）汽車集團）副總裁
- Protocol secretary in the Korean Presidential Palace  
韓國總統府禮賓司秘書
- Assistant Professor of Finance at the University of Alberta in Edmonton  
埃德蒙頓阿爾伯塔大學金融學助理教授
- Massachusetts Institute of Technology (Ph.D. in Economics) 1987  
1987年畢業于麻省理工學院（經濟學博士）

# Board of Directors

## 董事會成員

**Yunji Kim**  
*President, CEO and Director*  
總裁、首席執行官兼董事

---

- President since April 2013, Director since October 2012  
2013年4月起擔任總裁；  
2012年10月起擔任董事
- New York State Bar admission 2012  
2012年加入紐約州律師協會
- LL.M. in Taxation, Georgetown University Law Center, 2011  
2011年獲得了喬治敦大學法學院法學碩士學位

**Peter Chen**  
*CFO and Director*  
首席財務官兼董事

---

- Executive Director of Proterra Management Group Inc.  
目前在私營諮詢公司Proterra Management Group Inc.擔任執行董事。

**Dr. Terrance Owen**  
*Terrance Owen 博士*  
*Director*  
董事

---

- Director of Pacific Paradyne Energy Inc.  
目前擔任Pacific Paradyne Energy Inc. 董事
- CEO of CellMedX Corp.  
擔任CellMedx Corp. 首席執行官
- President and CEO of Nuva Pharmaceuticals Inc. until June 2013  
2013年6月前曾擔任Nuva Pharmaceuticals Inc. 的總裁兼首席執行官。

**Dr. Marcus Kuypers**  
*Marcus Kuypers 博士*  
*Director*  
董事

---

- Medical Doctor  
醫學博士
- Physician at AB Staffing since November 2011  
自2011年11月至今一直是AB Staffing的在職醫生
- Accretive Health from October 2011 to February 2013  
2011年10月至2013年2月任職於Accretive Health
- Doctors Home Visits from September 2001 to August 2011  
2001年9月至2011年8月在Doctors Home Visits供職
- Emergency Medicine physician since November 2011  
自2011年11月至今，一直擔任急救醫生。

## Appendix - Financial Information

### 附錄——財務信息

**Most updated information available upon request**

請在網站上申請獲取公司最新信息

[www.eleotin.ca](http://www.eleotin.ca)

[www.eleotin.cn](http://www.eleotin.cn)



TSX-V: EBM

Yunji Kim

Unit 1130-4871 Shell Road Richmond, B.C. Canada, V6X 3Z6

604.247.2100 or 1.888.669.4372

[yunjikim@eastwoodcos.com](mailto:yunjikim@eastwoodcos.com)

[www.eleotin.ca](http://www.eleotin.ca)

[www.eleotin.cn](http://www.eleotin.cn)